HNO210 Cells
USD$800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The HNO210 cell line is derived from a laryngeal squamous cell carcinoma, a subtype of head and neck squamous cell carcinoma (HNSCC). This cell line has been extensively characterized for its genetic and molecular features, making it a valuable model for studying the pathogenesis and treatment responses of HNSCC. Chromosomal comparative genomic hybridization (cCGH) analysis of HNO210 has revealed several significant chromosomal aberrations. Notably, it exhibits DNA copy number gains in chromosomal regions 3q, 7p, 7q, 9p, 9q, 20p, and 20q, and copy number losses in 3p, 4p, 4q, and chromosome 21. These genetic alterations are common in HNSCC and are associated with aggressive tumor behavior and poor patient prognosis. In particular, the amplification of regions such as 3q and 11q13, which is seen in many HNSCC cell lines, is of interest due to its correlation with increased expression of oncogenes such as CCND1 (cyclin D1) and CTTN (cortactin). These genes are involved in cell cycle regulation and cytoskeletal organization, respectively, and their overexpression can contribute to enhanced cell proliferation, invasion, and metastasis. The HNO210 cell line, with its distinct genetic profile, serves as a robust model for investigating the molecular mechanisms underlying laryngeal cancer progression and for testing targeted therapies that address these specific genetic abnormalities. Additionally, this cell line is part of a panel used to explore the efficacy of combination therapies, such as the use of cisplatin with thalidomide, which have shown promise in enhancing anti-tumor activity in vitro and in vivo. This makes HNO210 not only crucial for basic cancer research but also for translational studies aimed at improving therapeutic outcomes for patients with HNSCC. |
|---|---|
| Organism | Human |
| Tissue | Larynx |
| Disease | Head and neck squamous cell carcinoma (HNSCC) |
Characteristics
| Age | 69 years |
|---|---|
| Gender | Male |
| Ethnicity | Caucasian |
| Morphology | Epithelial-like |
| Growth properties | Monolayer, adherent |
Regulatory Data
| Citation | HNO210 (Cytion catalog number 300134) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_D215 |
Biomolecular Data
Handling
| Culture Medium | DMEM, w: 4.5 g/L Glucose, w: 4 mM L-Glutamine, w: 3.7 g/L NaHCO3, w: 1.0 mM Sodium pyruvate (Cytion article number 820300a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 300134-321 | Certificate of Analysis | 23. May. 2025 | 300134 |